Method of inhibiting oxidants using alkylaryl polyether alcohol polymers
Patent 5512270 Issued on April 30, 1996. Estimated Expiration Date: 
August 31, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
August 31, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References 2454541 3663230 Composition for topical application and use thereof Lung surfactant compositions Methods and compositions for the treatment of lung conditions Lung surfactant compositions Methods employing unique mixtures of polar and neutral lipids for surfactant replacement therapy Patent #: 5134129 InventorsAssigneeApplicationNo. 299316 filed on 08/31/1994US Classes:424/45, Organic pressurized fluid424/78.05, Anti-inflammatory or anti-irritant (e.g., anti-arthritic, etc.)424/78.06, Skin burn or open wound treatment424/78.08, SOLID SYNTHETIC ORGANIC POLYMER AS DESIGNATED ORGANIC ACTIVE INGREDIENT (DOAI)424/78.37, Monomer contains oxygen514/887Topical TreatmentExaminersPrimary: Marquis, Melvyn I.Assistant: Harrison, Robert H. Attorney, Agent or FirmInternational ClassA61K 031/045AbstractThe present invention relates to use of alkylaryl polyether alcohol polymers as antioxidants to suppress certain oxidant chemical reactions that cause tissue injury and disease in mammals. Disclosed is a method of inhibiting oxidants using alkylaryl polyether alcohol polymers. More particularly, disclosed is a method for the treatment of mammalian disease entities related to overproduction of partially reduced oxygen species comprising administering to a mammal a treatment effective amount of an alkylaryl polyether alcohol polymer. The mammalian disease entities include, but are not limited to, myocardial infarction, stroke, adult respiratory distress syndrome, oxygen toxicity of the lung, lung injury from asbestos, Parkinson's disease, thermal and solar burns of the skin, and injury to the gastrointestinal tract from nonsteroidal anti-inflammatory agents.Other References
Field of SearchOrganic pressurized fluidSkin cosmetic coating Anti-inflammatory or anti-irritant (e.g., anti-arthritic, etc.) Skin burn or open wound treatment Monomer contains oxygen SOLID SYNTHETIC ORGANIC POLYMER AS DESIGNATED ORGANIC ACTIVE INGREDIENT (DOAI) Lecithins Topical Treatment OINTMENT OR SALVE BASE CHARACTERIZED BY THE DESIGNATED SURFACTANT USED | |
